Pradaxa - Articles and news items

Blood clot deep vein thrombosis Venous thromboembolism pulmonary embolism

Venous thromboembolism (VTE) therapeutics market set to hit $3.7 billion by 2025

Industry news / 1 August 2016 / GlobalData

Growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says new report…

AF Patients fail to receive recommended treatment

Many AF patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

Industry news / 17 March 2015 / Victoria White

AF patients considered at high risk for stroke may not be receiving recommended treatment as revealed in analyses from the GLORIA™-AF Registry Program…

Boehringer Ingelheim logo

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

Industry news / 19 November 2014 / Boehringer Ingelheim

Two new real-world data analyses presented at the American Heart Association’s Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin…

Boehringer Ingelheim logo

New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism

Industry news / 10 December 2013 / Boehringer Ingelheim

The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics…

Professor Gregory Lip, Consultant Cardiologist & Professor of Cardiovascular Medicine, University of Birmingham Centre for Cardiovascular Sciences, Birmingham, United Kingdom

Pradaxa® (dabigatran etexilate) receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK

Industry news, News / 19 March 2012 / NICE

Pradaxa® must now be made available for use by the UK National Health Service (NHS)…

Prof. Antonio Dans

Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke

Industry news, News / 28 August 2011 / Boehringer Ingelheim

In patients with atrial fibrillation taking antiplatelet or other concomitant therapies…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...